Current scientific evidence is insufficient to determine whether transgender status or gender-affirming hormone therapy is associated with the risk of developing heart failure, according to a systematic review published in BMC Medicine. While heart failure represents a major cardiovascular condition with a well-characterised epidemiology in the general population, researchers found that existing studies evaluating transgender populations remain constrained by severe methodological fragmentation and inconsistent study designs.
Cardiovascular risk factors have previously been examined in transgender individuals receiving gender-affirming hormone therapy, yet specific evidence evaluating heart failure outcomes in this group has remained scattered across diverse and heterogeneous epidemiological datasets. To address this knowledge gap, a research team led by Lavinia Rech and Erlon O. de Abreu-Silva set out to synthesise available evidence on heart failure in transgender populations and systematically evaluate the methodological factors influencing risk assessment.
The investigators conducted a systematic review that incorporated both administrative health databases and clinical datasets reporting heart failure outcomes in transgender cohorts. For investigations that provided extractable statistical estimates alongside documented or inferred hormone therapy exposure and an identifiable cisgender comparator group, the authors performed exploratory random-effects quantitative syntheses while assessing transgender identification methods, exposure ascertainment, outcome definitions, comparator selection, and study-level risk of bias.
Across the published medical literature, the research team identified only a limited number of eligible investigations, with just seven full-text studies meeting all inclusion criteria. A critical finding of the review was that transgender identification methods, hormone exposure ascertainment protocols, heart failure definitions, comparator groups, and baseline demographic characteristics varied substantially across the included publications.
When the researchers conducted exploratory quantitative syntheses that incorporated suitable conference abstracts alongside full-text publications, the resulting pooled estimates were statistically non-significant yet demonstrated extreme statistical heterogeneity, both when comparing transgender to cisgender individuals and when contrasting transgender men with cisgender women.
Specifically, the exploratory random-effects analysis comparing transgender individuals to cisgender comparators yielded a pooled odds ratio of 1.10 with a 95% confidence interval ranging from 0.60 to 2.01, accompanied by an I-squared heterogeneity value of 98.9%. Similarly, the quantitative synthesis contrasting transgender men with cisgender women produced an odds ratio of 1.04 with a 95% confidence interval of 0.38 to 2.86, alongside an I-squared heterogeneity measurement of 99.5%.
A notable clinical gap highlighted by the systematic review is that none of the evaluated studies systematically distinguished between distinct heart failure phenotypes. This absence of phenotype classification, combined with variable population identification techniques and exposure assessment strategies, represents a major structural barrier that directly prevents researchers from drawing definitive conclusions regarding cardiovascular risk.
The authors conclude that these structural limitations constrain heart failure risk evaluation in transgender populations.
Because the exploratory quantitative syntheses revealed pronounced statistical variation, with heterogeneity exceeding 98 percent across the pooled analyses, the authors emphasized that resolving these clinical uncertainties requires systemic improvements in epidemiological data infrastructure.
Subject of Research: Heart failure risk assessment and methodological limitations in transgender health research
Article Title: Heart failure in transgender people: evidence synthesis and methodological limitations
Article References: Rech, L., Siqueira, A., Siqueira, S., Siepmann, T., & de Abreu-Silva, E. O. (2026). Heart failure in transgender people: evidence synthesis and methodological limitations. BMC Medicine. https://doi.org/10.1186/s12916-026-05399-2
Image Credits: AI Generated
DOI: 10.1186/s12916-026-05399-2
Keywords: heart failure, transgender health, gender-affirming hormone therapy, systematic review, cardiovascular risk, epidemiology, methodological limitations, clinical datasets, administrative datasets, heart failure phenotypes, cisgender comparator, transgender men, cisgender women, heterogeneity, cardiovascular registries, odds ratio
News Source: Ophelia Keating. (November 12, 2026). Current Evidence Cannot Determine Heart Failure Risk in Transgender People. Scienmag.



